Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

AIM: The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. METHODS: In this randomized, double-blind, phase 3 study, patients (N = 342) received ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Forst, T, Guthrie, R, Goldenberg, R, Yee, J, Vijapurkar, U, Meininger, G, Stein, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237547/
https://www.ncbi.nlm.nih.gov/pubmed/24528605
http://dx.doi.org/10.1111/dom.12273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237547/
https://www.ncbi.nlm.nih.gov/pubmed/24528605
http://dx.doi.org/10.1111/dom.12273

Ejemplares similares